CXCR4 and tropical spastic paraparesis: Due to poor prognosis of patients diagnosed with ATL, coupled with limited therapeutic options, novel immunological approaches including recombinant IL-7, IFN-α, and neutralizing anti-CD25 or anti-CXCR4 antibodies are currently being used to treat ATL and HAM/TSP patients [50]–[53].